Table 1.
Comparison patient and treatment characteristics of HPV negative and HPV positive patients.
| HPV negative | HPV positive | P-value | |
|---|---|---|---|
| PATIENT AND TREATMENT CHARACTERISTICS | |||
| Gender | 0.347 | ||
| Male | 130/160 (81.25%) | 76/100 (76.00%) | |
| Female | 30/160 (18.75%) | 24/100 (24.00%) | |
| Age | 0.030 | ||
| Median (IQR) | 59.7 (54.0-65.8) | 63.6 (54.9-70.1) | |
| Smoking | <0.001 | ||
| mean pack years (SD) | 38.8 (22.12) | 22.6 (21.65) | |
| Never smoker | 3/160 (1.88%) | 27/100 (27.00%) | |
| ≤ 10 Pack years | 8/160 (5.00%) | 14/100 (14.00%) | |
| >10 Pack years | 147/160 (91.87%) | 56/100 (57.00%) | |
| Unknown | 2/160 (1.25%) | 3/100 (3.00%) | |
| Systemic Treatment | 0.076 | ||
| No | 46/160 (28.75%) | 31/100 (31.00%) | |
| Cisplatin | 97/160 (60.63%) | 66/100 (66.00%) | |
| EGFR-inhibitor | 17/160 (17.00%) | 3/100 (3.00%) | |
| Comorbidity: ACE27 | 0.007 | ||
| 0 | 26/160 (16.25%) | 31/100 (31.00%) | |
| 1 | 64/160 (40.00%) | 37/100 (37.00%) | |
| 2 | 38/160 (23.75%) | 24/100 (24.00%) | |
| 3 | 32/160 (20.00%) | 8/100 (8.00%) | |
HPV, Human papillomavirus; IQR, Interquartile range; SD, Standard Deviation; ACE27, Adult Comorbidity Evaluation 27. Bold values p < 5% significance level.